Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shirley Hodgson

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Nature Genetics|September 6, 2011
Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)Pia Ostergaard, Michael A Simpson, Fiona C Connell, et al.
The Journal of Clinical Endocrinology and Metabolism|May 24, 2007
Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasiaMarianthi Georgitsi, Anniina Raitila, Auli Karhu, et al.
The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.
Carcinogenesis|October 4, 2011
Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer StudyCatherine S Healey, Shahana Ahmed, , et al.
The Lancet. Oncology|November 13, 2012
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialJohn C Mathers, Mohammad Movahedi, Finlay Macrae, et al.
Journal of the National Cancer Institute|May 1, 2013
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACENasim Mavaddat, Susan Peock, Debra Frost, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancerElena Castro, Chee Goh, David Olmos, et al.
Plos One|October 23, 2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineHayley C Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.
Nature Genetics|September 6, 2011
Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)Pia Ostergaard, Michael A Simpson, Fiona C Connell, et al.
The Journal of Clinical Endocrinology and Metabolism|May 24, 2007
Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasiaMarianthi Georgitsi, Anniina Raitila, Auli Karhu, et al.
The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.
Carcinogenesis|October 4, 2011
Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer StudyCatherine S Healey, Shahana Ahmed, , et al.
The Lancet. Oncology|November 13, 2012
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialJohn C Mathers, Mohammad Movahedi, Finlay Macrae, et al.
Journal of the National Cancer Institute|May 1, 2013
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACENasim Mavaddat, Susan Peock, Debra Frost, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancerElena Castro, Chee Goh, David Olmos, et al.
Plos One|October 23, 2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineHayley C Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, et al.
Pageof 8